Literature DB >> 2800578

Myocardial infarction after dipyridamole-assisted thallium-201 imaging.

P Biddle1, T J Lanspa, S M Mohiuddin, M A Malesker, D E Hilleman.   

Abstract

A 77-year-old woman with suspected coronary artery disease underwent an oral dipyridamole/thallium-201 myocardial imaging study. Approximately 75 minutes after ingestion of dipyridamole 300 mg suspension, the patient developed chest pain, hypotension, nausea, and diaphoresis. An electrocardiogram revealed ST-T wave changes suggestive of inferior ischemia. Appropriate therapeutic measures, including aminophylline and nitroglycerin, were instituted. Delayed thallium images revealed reversible ischemia in the anteroseptal and posterobasal regions with a fixed defect in the inferobasal region. Cardiac enzyme studies were also indicative of acute myocardial injury. The patient subsequently underwent coronary arteriography and four-vessel coronary artery bypass grafting and was discharged without further complication. This report raises concerns about the potential danger of dipyridamole in patients with severe coronary artery stenosis and collateral circulation. Prophylactic aminophylline should be considered in these patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2800578     DOI: 10.1177/106002808902300907

Source DB:  PubMed          Journal:  DICP        ISSN: 1042-9611


  3 in total

1.  Cardiogenic shock after dipyridamole administration for myocardial perfusion imaging.

Authors:  Fahim H Jafary; Nageeb Basir; Adnan Amin; Nasiruddin Ahmed
Journal:  J Nucl Cardiol       Date:  2005 May-Jun       Impact factor: 5.952

2.  Myocardial infarction secondary to dipyridamole overdose.

Authors:  M Jahangiri; D R Holdright
Journal:  Arch Emerg Med       Date:  1992-03

3.  Safety of dipyridamole testing in 73,806 patients: the Multicenter Dipyridamole Safety Study.

Authors:  J Lette; J L Tatum; S Fraser; D D Miller; D D Waters; G Heller; E B Stanton; H S Bom; J Leppo; S Nattel
Journal:  J Nucl Cardiol       Date:  1995 Jan-Feb       Impact factor: 5.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.